MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
4.880
+0.370
+8.20%
After Hours: 4.728 -0.152 -3.11% 19:07 02/06 EST
OPEN
4.580
PREV CLOSE
4.510
HIGH
4.920
LOW
4.580
VOLUME
100.03K
TURNOVER
--
52 WEEK HIGH
19.15
52 WEEK LOW
4.200
MARKET CAP
35.19M
P/E (TTM)
2.224
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATRA last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at ATRA last week (0119-0123)?
Weekly Report · 01/26 10:16
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
TipRanks · 01/19 16:30
Weekly Report: what happened at ATRA last week (0112-0116)?
Weekly Report · 01/19 10:22
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/15 17:05
Panacea Innovation Ltd Sells Common Shares of Atara Biotherapeutics Inc
Reuters · 01/15 02:16
Atara Biotherapeutics Cut to Hold From Buy by Canaccord Genuity
Dow Jones · 01/13 20:28
Atara Biotherapeutics Price Target Cut to $6.00/Share From $25.00 by Canaccord Genuity
Dow Jones · 01/13 20:28
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.